Levy Richard S. has maintained a consistently one-sided posture in his SEC Form 4 filings, with no open-market purchases recorded across 41 transactions spanning four companies. The aggregate sell value stands at approximately $7.34 million, all of it concentrated in Madrigal Pharmaceuticals (MDGL), where the bulk of his recent activity has occurred. On May 22, 2026, Levy executed a cluster of ten open-market sales in MDGL, ranging from roughly $20,000 to $775,000 per transaction and totaling about $2.73 million on that single day. A smaller sale on November 13, 2025, added roughly $359,000, while an option exercise on February 23, 2026, valued at $18,400, and another on January 26, 2026, at $65,840, preceded some of the selling.
The remaining filings are non-discretionary or compensatory in nature. Levy received grants (code A) with zero dollar values across Kodiak Sciences (KOD), Madrigal, Protara Therapeutics (TARA), and Kiniksa Pharmaceuticals (KNSA) between February and June 2026, alongside option exercises (code M) in KNSA and MDGL that carried no cash value. Notably, there are no recent purchases (code P) or sales back to issuers (code D) in the data, reinforcing that Levy’s only market transactions are sell-side. The pattern is clear: a
AI-assisted summary